CytoSorbents Corp (CTSO) Q3 2026 Earnings Call Highlights: Cash Flow Breakeven

CytoSorbents Corp (CTSO) achieved operating cash flow breakeven in Q3 2026, driven by improved gross margins, reduced expenses, and narrower EBITDA loss. CEO Dr. Philip Chan discussed regulatory timelines, market opportunities, and clinical evidence for DrugSorb ATR. The company plans to address Germany sales decline and explore strategic alternatives for HemoDefend BGA.

Original reporting
Published Nov 13, 2026, 5:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 5:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CytoSorbents Corp (CTSO) Q3 2026 Earnings Call Highlights: Cash Flow Breakeven — source image
Decision brief

The 30-second read

$CTSONeutralHigh
01

Why it matters

Earnings call provides fresh quantitative data and forward‑looking regulatory guidance, offering traders a basis for short‑term positioning.

02

Market read

Micro‑cap earnings with cash‑flow breakeven could trigger short‑term price movement; broader market impact limited.

03

What to watch

Potential dilution from upcoming debt restructuring and Nasdaq listing compliance costs.

Relevance 7/10Novelty 8/10Timing: post‑earnings release today

Background

CytoSorbents discussed Q3 results, cash‑flow status, margin trends, and regulatory timelines for its DrugSorb ATR device.

Company-level read

Ticker impact

$CTSONeutralHigh confidence
Context

Q3 2026 earnings call disclosed operating cash flow breakeven, margin expansion and revenue of $9.7M, new guidance on FDA de novo submission and market opportunity.

Expected impact

likely modest upside as investors price in cash‑flow breakeven, but pressure if FDA review delays materialize

Evidence & confidence

First report of cash‑flow breakeven and detailed margin data provides fresh material; however, the company remains micro‑cap with high execution risk.

Market effects

Highlights progress in medical device sector and may influence peer valuations in blood‑filter technologies.

Limited to US micro‑cap market; no broader regional effect.

Minimal global impact beyond niche biotech investors.

Counterpoint

Cash‑flow breakeven may be temporary; execution risk on FDA de novo could lead to downside.

Key entities

  • CytoSorbents Corp

    Medical device maker reporting Q3 2026 results.

  • Dr. Philip Chan

    CEO providing guidance on FDA timeline and market opportunity.

Related articles

$CTSOMed

CytoSorbents Reports Third Quarter 2026 Financial Results, Achieves Operating Cash Flow Breakeven, and Provides Business and Regulatory Update Delivering on…

Cytosorbents Corp (CTSO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CytoSorbents Reports Third Quarter 2026 Financial Results, Achieves Operating Cash Flow Breakeven, and Provides Business and Regulatory Update Delivering on the First of Four Distinct Value Drivers PRINCETON, N.J., November 12, 2026 — CytoSorbents Corporation (NASDAQ

$CTSOMed

Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript

Cytosorbents (CTSO) reported Q2 2026 revenue of $9.6 million, flat vs. the prior year and up 9% sequentially, with 73% gross margin. Adjusted EBITDA loss was $1.6 million, a 38% improvement. Net loss was $4.4 million. Management discussed FDA strategy for DrugSorb-ATR after a de novo denial, and progress on HemoDefend-BGA. Cash was $5.9 million.

$CTSOMed

CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of…

Cytosorbents Corp (CTSO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of Shareholder Value PRINCETON, N.J., August 6, 2026 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatme

$CTSOMedAI 9/10

Cytosorbents (CTSO) Q1 2026 Earnings Transcript

Cytosorbents (CTSO) reported Q1 2026 revenue of $8.9 million, up 2% YoY, with direct international markets (excluding Germany) up 13% while Germany declined. Gross margin fell to 69% from 71%. Adjusted EBITDA loss narrowed to $2.2 million (vs. $2.7 million), as operating expenses dropped to $9.2 million. Net loss was $5.1 million ($0.08/share). FDA said DrugSorb-ATR needs additional non-clinical data and real-world evidence for a de novo submission, likely pushing timing to late 2026/early 2027.